Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive DisorderLinda J. Bristow, Michael Sinz, Jyoti Gulia et al.|Journal of Pharmacology and Experimental Therapeutics|2017Cited by 17
BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive DisorderLawrence R. Marcin, John E. Macor, Aliphedi B. Reddy et al.|ACS Medicinal Chemistry Letters|2018Cited by 17
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic PropertiesMatthew D. Hill, Andrew P. Degnan, Haiquan Fang et al.|ACS Medicinal Chemistry Letters|2022Cited by 10
CCDC 1831022: Experimental Crystal Structure DeterminationLawrence R. Marcin, John E. Macor, Jayakumar Warrier et al.|The Cambridge Structural Database|2018Cited by 0
CCDC 1827708: Experimental Crystal Structure DeterminationLawrence R. Marcin, John E. Macor, Jayakumar Warrier et al.|The Cambridge Structural Database|2018Cited by 0